Early Results of Sotatercept Treatment in Patients With Severe Pulmonary Hypertension and a Potts Shunt

Pulmonary arterial hypertension (PAH) patients frequently present with cardiometabolic comorbidities and experience substantial hematologic and cardiovascular events.

Pediatric idiopathic pulmonary arterial hypertension (IPAH) refractory to maximal medical therapy is associated with high morbidity and mortality, and therapeutic options remain limited.

Pregnancy in pulmonary arterial hypertension (PAH) is associated with substantial risks. Endothelin receptor antagonists (ERAs), including macitentan and bosentan, are contraindicated in pregnancy due to teratogenic effects observed in animal studies.

Pretreatment with targeted pulmonary arterial hypertension (PAH) therapy in adults with unrepaired atrial septal defects (ASDs) has been increasingly reported as a means to improve pulmonary hemodynamics and expand candidacy for defect closure.